Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 5, 2015, Pages 459-466

  Dultz, G ^a   Piiper, A ^a   Zeuzem, S ^a   Kronenberger, B ^a   Waidmann, O ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; METICILLIN; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; VANCOMYCIN;

ADULT; AGED; ARTICLE; ASCITES; BACTERIAL INFECTION; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; EPIGASTRIC PAIN; ESOPHAGUS VARICES; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GERMANY; GRAM NEGATIVE BACTERIUM; HAZARD RATIO; HEPATORENAL SYNDROME; HUMAN; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; OVERALL SURVIVAL; PEPTIC ULCER; PREDICTION; PRESCRIPTION; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; UNIVERSITY HOSPITAL; VANCOMYCIN RESISTANT ENTEROCOCCUS; VERY ELDERLY; VOMITING; AGE; BACTERIAL INFECTIONS; CLINICAL TRIAL; INCIDENCE; LIVER DISEASE; MICROBIOLOGY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; STATISTICAL MODEL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BACTERIAL INFECTIONS; FEMALE; GERMANY; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 84921909302     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13061     Document Type: Article

References (30)

1. Wallace K, Burt AD, Wright MC,. Liver fibrosis. Biochem J 2008; 411: 1-18.
2. Ginès P, Angeli P, Lenz K, et al,. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417.
3. Cárdenas A, Ginès P,. Management of patients with cirrhosis awaiting liver transplantation. Gut 2011; 60: 412-21.
4. Garcia-Tsao G, Bosch J,. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010; 362: 823-32.
5. Lodato F, Azzaroli F, Di Girolamo M, et al,. Proton pump inhibitors in cirrhosis: tradition or evidence based practice? World J Gastroenterol 2008; 14: 2980-5.
6. Shaheen NJ, Stuart E, Schmitz SM, et al,. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. Hepatology 2005; 41: 588-94.
7. Trikudanathan G, Israel J, Cappa J, O'Sullivan DM,. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients-a systematic review and meta-analysis. Int J Clin Pract 2011; 65: 674-8.
8. Bajaj JS, Ratliff SM, Heuman DM, Lapane KL,. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther 2012; 36: 866-74.
9. Goel GA, Deshpande A, Lopez R, Hall GS, van Duin D, Carey WD,. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol 2012; 10: 422-7.
10. Deshpande A, Pasupuleti V, Thota P, et al,. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol 2013; 28: 235-42.
11. Kwon JH, Koh S, Kim W, et al,. Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis. J Gastroenterol Hepatol 2014; 29: 775-81.
12. de Vos M, de Vroey B, Garcia BG, et al,. Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Liver Int 2013; 33: 1316-23.
13. Ramsay EN, Pratt NL, Ryan P, Roughead EE,. Proton pump inhibitors and the risk of pneumonia: a comparison of cohort and self-controlled case series designs. BMC Med Res Methodol 2013; 13: 82.
14. MacLaren R, Reynolds PM, Allen RR,. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med 2014; 174: 564-74.
15. Fernández J, Acevedo J, Castro M, et al,. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55: 1551-61.
16. Stiefel U, Rao A, Pultz MJ, Jump RLP, Aron DC, Donskey CJ,. Suppression of gastric acid production by proton pump inhibitor treatment facilitates colonization of the large intestine by vancomycin-resistant Enterococcus spp. and Klebsiella pneumoniae in clindamycin-treated mice. Antimicrob Agents Chemother 2006; 50: 3905-7.
17. McNeil SA, Malani PN, Chenoweth CE, et al,. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis 2006; 42: 195-203.
18. Llovet JM, Ducreux M, Lencioni R, et al,. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
19. Kamath PS, Wiesner RH, Malinchoc M, et al,. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
20. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R,. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
21. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM,. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180-4.
22. Leontiadis GI, Sharma VK, Howden CW,. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2006; (1): CD002094.
23. Kalaitzakis E, Björnsson E,. Inadequate use of proton-pump inhibitors in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2008; 20: 512-8.
24. Chavez-Tapia NC, Tellez-Avila FI, Garcia-Leiva J, Valdovinos MA,. Use and overuse of proton pump inhibitors in cirrhotic patients. Med Sci Monit 2008; 14: CR468-72.
25. Bauer TM, Schwacha H, Steinbrückner B, et al,. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol 2002; 97: 2364-70.
26. Parkman HP, Urbain JL, Knight LC, et al,. Effect of gastric acid suppressants on human gastric motility. Gut 1998; 42: 243-50.
27. Yoshida N, Yoshikawa T, Tanaka Y, et al,. A new mechanism for anti-inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 2000; 14 (Suppl 1): 74-81.
28. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxböck F, Graninger W,. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002; 30: 1118-22.
29. Bajaj JS, Ananthakrishnan AN, Hafeezullah M, et al,. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol 2010; 105: 106-13.
30. Thjodleifsson B,. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors. Drugs Aging 2002; 19: 911-27.